|Founder||Dr. Michael W. Fanger |
Dr. Paul M. Guyre
Dr. Edward D. Ball
|Fate||Acquired by Bristol Myers Squibb|
|Headquarters||Princeton, New Jersey, US.|
|Parent||Bristol Myers Squibb|
Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.
Medarex developed monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as "brakes" on the T cell's anti-cancer activities. The monoclonal antibodies bind to these proteins and block them, releasing the T cell to attack cancer cells.
Several monoclonal antibodies developed by Medarex have been approved for disease therapy. In 2009, the U.S. Food and Drug Administration approved Simponi, a human monoclonal antibody to tumor necrosis factor alpha co-developed with Johnson & Johnson's Janssen Biotech, for treatment of arthritis. In 2011, the U.S. FDA approved ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma. In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma. Its use was expanded to the treatment of squamous non-small-cell lung carcinoma in 2015.
Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform.
Medarex was founded in 1987 by a group of immunologists at Dartmouth Medical School—Dr. Michael W. Fanger, Dr. Paul M. Guyre, and Dr. Edward D. Ball — who partnered with Donald L. Drakeman and Charles Schaller of Essex Chemical Company, through its venture capital arm Essex Vencap.
Drakeman, a Dartmouth graduate, brought the parties together and served as the company's chief executive officer. The company went public in 1991, with 2,300,000 shares of common stock at $6.10 per share and 2,250,000 Redeemable Warrants offered at its IPO. The company's second president and CEO was Howard H. Pien, succeeding Drakeman in 2007. Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999.
- Breakthrough of the Year: Cancer Immunotherapy, Science 20 December 2013, Vol. 342 no. 6165 pp. 1432-1433, DOI: 10.1126/science.342.6165.1432, Jennifer Couzin-Frankel
- Clinical trial number NCT00094653 for "MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma" at ClinicalTrials.gov
- Marcial, Gene (4 May 2009). "Marcial: Medarex, a Bright Spot in Biotech". businessweek.com. Retrieved 24 Sep 2014.
- "Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration - BMS Newsroom". news.bms.com.
- "FDA Expands Approved Use of Nivolumab to Squamous NSCLC - ESMO". www.esmo.org.
- Pierson, Ransdell (2009-07-23). "Bristol-Myers to buy Medarex for $2.4 billion". Reuters. Retrieved 2021-04-14.
- Booth, Bruce. "Human Antibody Discovery: Of Mice And Phage". Forbes. Retrieved 2021-04-14.
- "Medarex raises $12.9M in IPO for R&D of Biospecific". 1 May 1991. Retrieved 24 Sep 2014.
- "Life in the Fast Lane: New at Medarex". pharmamedtechbi.com. 23 May 2007. Retrieved 24 Sep 2014.
- "Final tally on Genmab IPO reaches $582M". www.bioworld.com. Retrieved 2020-09-10.
- Dealbook Blog, New York Times. July 23, 2009 Bristol-Myers to Buy Medarex For $2.4 Billion
- John Carroll for FierceBiotech Jul 23, 2009 Bristol-Myers to buy Medarex for $2.1B
- medarex.com is now BMS.com Corporate website